The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Abstract
BACKGROUND: In this phase 2, randomized, double-blind, placebo-controlled, dose-ranging study, we assessed the efficacy and safety of brodalumab (AMG 827), a human anti-interleukin-17-receptor monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis. METHODS: We randomly assigned patients with a score of 12 or higher on the psoriasis area-and-severity index (PASI, on which scores range from 0 to 72, with higher scores indicating more severe disease) and with 10% or more of their body-surface area affected by psoriasis to receive brodalumab (70 mg, 140 mg, or 210 mg at day 1 and weeks 1, 2, 4, 6, 8, and 10 or 280 mg monthly) or placebo. The primary end point was the percentage improvement from baseline in the PASI score at week 12. Secondary end points included improvement of at least 75% and at least 90% in the PASI score and the score on the static physician's global assessment at week 12. RESULTS: A total of 198 patients underwent randomization. At week 12, the mean percentage improvements in the PASI score were 45.0% among patients receiving 70 mg of brodalumab, 85.9% among those receiving 140 mg, 86.3% among those receiving 210 mg, 76.0% among those receiving 280 mg, and 16.0% among those receiving placebo (P<0.001 for all comparisons with placebo). An improvement of at least 75% and at least 90% in the PASI score at week 12 was seen in 77% and 72%, respectively, of the patients in the 140-mg brodalumab group and in 82% and 75%, respectively, of the patients in the 210-mg group, as compared with 0% in the placebo group (P<0.001 for all comparisons). The percentage of patients with a static physician's global assessment of clear or minimal disease was 26%, 85%, 80%, and 69% with the 70-mg, 140-mg, 210-mg, and 280-mg doses, respectively, of brodalumab, as compared with 3% with placebo (P<0.01 for all comparisons with placebo). Two cases of grade 3 neutropenia were reported in the 210-mg brodalumab group. The most commonly reported adverse events in the combined brodalumab groups were nasopharyngitis (8%), upper respiratory tract infection (8%), and injection-site erythema (6%). CONCLUSIONS: Brodalumab significantly improved plaque psoriasis in this 12-week, phase 2 study. (Funded by Amgen; ClinicalTrials.gov number, NCT00975637.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A.-M., Florencia, E., Prens, E. P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802999 · Cited by 2,176
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475
On closed testing procedures with special reference to ordered analysis of variance
MARCUS, R., ERIC, P., & GABRIEL, K. R. (1976) · Biometrika · doi:10.1093/biomet/63.3.655 · Cited by 1,423
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells
Lowes, M. A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L. C., Haider, A. S., Bowman, E. P., & Krueger, J. G. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701213 · Cited by 1,082
Self-citationAnti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 936
Self-citationHueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,650
Self-citationThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Self-citationAnti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 936
Self-citationTeng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J.-L., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 873
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512711 · Cited by 848
Self-citationGriffiths, C. E. M., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., Cameron, G. S., Erickson, J., Zhang, L., Secrest, R. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60125-8 · Cited by 834
Self-citationPhase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
Self-citationMcInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60594-2 · Cited by 807
Dialogue between skin microbiota and immunity
Belkaid, Y., & Segre, J. A. (2014) · Science · doi:10.1126/science.1260144 · Cited by 749
Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
Steven, S., Frenis, K., Oelze, M., Kalinovic, S., Kuntic, M., Bayo Jimenez, M. T., Vujacic-Mirski, K., Helmstädter, J., Kröller-Schön, S., Münzel, T., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7092151 · Cited by 708
Busse, W. W., Holgate, S., Kerwin, E., Chon, Y., Feng, J., Lin, J., & Lin, S.-L. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201212-2318oc · Cited by 666
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Self-citationBaeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J. M., Landewé, R., Wordsworth, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61134-4 · Cited by 595
Neutrophilic Inflammation in Asthma and Association with Disease Severity
Ray, A., & Kolls, J. K. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.07.003 · Cited by 546
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.005 · Cited by 537
Self-citationThe Role of IL-17 and related cytokines in inflammatory autoimmune diseases
Kuwabara, T., Ishikawa, F., Kondo, M., & Kakiuchi, T. (2017) · Mediators of Inflammation · doi:10.1155/2017/3908061 · Cited by 519
Mechanisms of human autoimmunity
Rosenblum, M. D., Remedios, K. A., & Abbas, A. K. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78088 · Cited by 515
Innate lymphoid cells in the initiation, regulation and resolution of inflammation
Sonnenberg, G. F., & Artis, D. (2015) · Nature Medicine · doi:10.1038/nm.3892 · Cited by 503
Papp, K. A., Reich, K., Paul, C., Blauvelt, A., Baran, W., Bolduc, C., Toth, D., Langley, R. G., Cather, J., Gottlieb, A. B., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14493 · Cited by 470
Self-citationThe Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
Martin, D. A., Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G., & Russell, C. B. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.194 · Cited by 466
Self-citationThe IL-23-IL-17 axis in inflammatory arthritis
Lubberts, E. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.53 · Cited by 442
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
McAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J. C., Lankapalli, R. H., Zhang, H., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.014 · Cited by 405
Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis
Cheuk, S., Wikén, M., Blomqvist, L., Nylén, S., Talme, T., Ståhle, M., & Eidsmo, L. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302313 · Cited by 413
IL-17 in Chronic Inflammation: From Discovery to Targeting
Beringer, A., Noack, M., & Miossec, P. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.001 · Cited by 402
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Mease, P. J., Genovese, M. C., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A. D., Deodhar, A., Newmark, R., Feng, J., Erondu, N., & Nirula, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315231 · Cited by 395
Atreya, R., Neumann, H., Neufert, C., Waldner, M. J., Billmeier, U., Zopf, Y., Willma, M., App, C., Münster, T., Kessler, H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3462 · Cited by 392
New anti-inflammatory targets for chronic obstructive pulmonary disease
Barnes, P. J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4025 · Cited by 392
CD5L/AIM Regulates Lipid Biosynthesis and Restrains Th17 Cell Pathogenicity
Wang, C., Yosef, N., Gaublomme, J., Wu, C., Lee, Y., Clish, C. B., Kaminski, J., Xiao, S., Zu Horste, G. M., Pawlak, M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.068 · Cited by 392
New insights of T cells in the pathogenesis of psoriasis
Cai, Y., Fleming, C., & Yan, J. (2012) · Cellular & Molecular Immunology · doi:10.1038/cmi.2012.15 · Cited by 389
Compartmentalized and systemic control of tissue immunity by commensals
Belkaid, Y., & Naik, S. (2013) · Nature Immunology · doi:10.1038/ni.2604 · Cited by 382
Targan, S. R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G. Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.298 · Cited by 383
Self-citationEssentials of Th17 cell commitment and plasticity
Muranski, P., & Restifo, N. P. (2013) · Blood · doi:10.1182/blood-2012-09-378653 · Cited by 383
IL-17 in Severe Asthma. Where Do We Stand?
Chesné, J., Braza, F., Mahay, G., Brouard, S., Aronica, M., & Magnan, A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201405-0859pp · Cited by 377
Baliwag, J., Barnes, D. H., & Johnston, A. (2015) · Cytokine · doi:10.1016/j.cyto.2014.12.014 · Cited by 373
Fowler, V. G., Allen, K. B., Moreira, E. D., Moustafa, M., Isgro, F., Boucher, H. W., Corey, G. R., Carmeli, Y., Betts, R., Hartzel, J. S., et al. (2013) · JAMA · doi:10.1001/jama.2013.3010 · Cited by 372
Diagnosis and classification of psoriasis
Raychaudhuri, S. K., Maverakis, E., & Raychaudhuri, S. P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.008 · Cited by 370
Psoriasis: Which therapy for which patient
Kaushik, S. B., & Lebwohl, M. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.057 · Cited by 368
Interleukin-17 and innate immunity in infections and chronic inflammation
Isailovic, N., Daigo, K., Mantovani, A., & Selmi, C. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.04.006 · Cited by 363
Papp, K. A., Langley, R. G., Sigurgeirsson, B., Abe, M., Baker, D. R., Konno, P., Haemmerle, S., Thurston, H. J., Papavassilis, C., & Richards, H. B. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12110 · Cited by 360
Self-citationLotti, F., Jarrar, A. M., Pai, R. K., Hitomi, M., Lathia, J., Mace, A., Gantt, G. A., Sukhdeo, K., DeVecchio, J., Vasanji, A., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131195 · Cited by 359
Targeting Th17 cells in autoimmune diseases
Yang, J., Sundrud, M. S., Skepner, J., & Yamagata, T. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.07.006 · Cited by 348
Kudo, M., Ishigatsubo, Y., & Aoki, I. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00263 · Cited by 348
Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
Maxwell, J. R., Zhang, Y., Brown, W. A., Smith, C. L., Byrne, F. R., Fiorino, M., Stevens, E., Bigler, J., Davis, J. A., Rottman, J. B., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.019 · Cited by 342
“Antibodies to IL-17A or IL-17RA are also highly efficacious in psoriasis (Gordon et al., 2014; Langley et al., 2014; Papp et al., 2012), but surprisingly, they exacerbated Crohn’s disease in a subset of patients (Hueber et al.”
BackgroundInterleukin 17A: Toward a new understanding of psoriasis pathogenesis
Lynde, C. W., Poulin, Y., Vender, R., Bourcier, M., & Khalil, S. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.12.036 · Cited by 335
The Immunopathogenesis of Psoriasis
Kim, J., & Krueger, J. G. (2015) · Dermatologic Clinics · doi:10.1016/j.det.2014.09.002 · Cited by 331
Self-citationInterleukin-6: from an inflammatory marker to a target for inflammatory diseases
Rincon, M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.003 · Cited by 328
Blauvelt, A., Prinz, J. C., Gottlieb, A. B., Kingo, K., Sofen, H., Ruer-Mulard, M., Singh, V., Pathan, R., Papavassilis, C., Cooper, S., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13348 · Cited by 323
Sofen, H., Smith, S., Matheson, R. T., Leonardi, C. L., Calderon, C., Brodmerkel, C., Li, K., Campbell, K., Marciniak, S. J., Wasfi, Y., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.01.025 · Cited by 320
Self-citationDi Meglio, P., Villanova, F., & Nestle, F. O. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015354 · Cited by 317
Effect of IL-17A blockade with secukinumab in autoimmune diseases
Patel, D. D., Lee, D. M., Kolbinger, F., & Antoni, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202371 · Cited by 313
The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis
Girolomoni, G., Strohal, R., Puig, L., Bachelez, H., Barker, J., Boehncke, W. H., & Prinz, J. C. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14433 · Cited by 313
New targets for mucosal healing and therapy in inflammatory bowel diseases
Neurath, M. F. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.73 · Cited by 309
Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation
Johnston, A., Fritz, Y., Dawes, S. M., Diaconu, D., Al-Attar, P. M., Guzman, A. M., Chen, C. S., Fu, W., Gudjonsson, J. E., McCormick, T. S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201505 · Cited by 308
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Gordon, K. B., Duffin, K. C., Bissonnette, R., Prinz, J. C., Wasfi, Y., Li, S., Shen, Y.-K., Szapary, P., Randazzo, B., & Reich, K. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501646 · Cited by 306
Cytokines and the Skin Barrier
Hänel, K., Cornelissen, C., Lüscher, B., & Baron, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14046720 · Cited by 305
Tillack, C., Ehmann, L. M., Friedrich, M., Laubender, R. P., Papay, P., Vogelsang, H., Stallhofer, J., Beigel, F., Bedynek, A., Wetzke, M., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-302853 · Cited by 302
Daiber, A., Xia, N., Steven, S., Oelze, M., Hanf, A., Kröller-Schön, S., Münzel, T., & Li, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010187 · Cited by 297
Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
Armstrong, A. W., Puig, L., Joshi, A., Skup, M., Williams, D., Li, J., Betts, K. A., & Augustin, M. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.4029 · Cited by 294
Self-citationDeodhar, A., Mease, P. J., McInnes, I. B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1882-2 · Cited by 292
Self-citationXiao, S., Yosef, N., Yang, J., Wang, Y., Zhou, L., Zhu, C., Wu, C., Baloglu, E., Schmidt, D., Ramesh, R., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.004 · Cited by 276
Commensal Staphylococci Influence Staphylococcus aureus Skin Colonization and Disease
Parlet, C. P., Brown, M. M., & Horswill, A. R. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2019.01.008 · Cited by 276
Mease, P. J., & Armstrong, A. W. (2014) · Drugs · doi:10.1007/s40265-014-0191-y · Cited by 271
Saunte, D. M., Mrowietz, U., Puig, L., & Zachariae, C. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15015 · Cited by 270
Current knowledge on psoriasis and autoimmune diseases
McCormick, T., Ayala-Fontanez, N., & Soler, D. (2016) · Psoriasis: Targets and Therapy · doi:10.2147/ptt.s64950 · Cited by 266
Langley, R. G. B., Feldman, S. R., Nyirady, J., van de Kerkhof, P., & Papavassilis, C. (2015) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.865009 · Cited by 264
Suárez-Fariñas, M., Ungar, B., Noda, S., Shroff, A., Mansouri, Y., Fuentes-Duculan, J., Czernik, A., Zheng, X., Estrada, Y. D., Xu, H., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.06.032 · Cited by 262
Self-citationNakagawa, S., Matsumoto, M., Katayama, Y., Oguma, R., Wakabayashi, S., Nygaard, T., Saijo, S., Inohara, N., Otto, M., Matsue, H., et al. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.10.008 · Cited by 261
Karbach, S., Croxford, A. L., Oelze, M., Schüler, R., Minwegen, D., Wegner, J., Koukes, L., Yogev, N., Nikolaev, A., Reißig, S., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304108 · Cited by 261
IL-17 and Th17 Cells in Atherosclerosis: Subtle and Contextual Roles
Taleb, S., Tedgui, A., & Mallat, Z. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303567 · Cited by 260
Krueger, J. G., Ferris, L. K., Menter, A., Wagner, F., White, A., Visvanathan, S., Lalovic, B., Aslanyan, S., Wang, E. E. L., Hall, D., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.01.018 · Cited by 256
Self-citationT cells and the skin: from protective immunity to inflammatory skin disorders
Ho, A. W., & Kupper, T. S. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0162-3 · Cited by 241
Cytokines IL-17 and IL-22 in the host response to infection
Valeri, M., & Raffatellu, M. (2016) · Pathogens and Disease · doi:10.1093/femspd/ftw111 · Cited by 202
IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells
Bär, E., Whitney, P. G., Moor, K., Reis e Sousa, C., & LeibundGut-Landmann, S. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.002 · Cited by 197
Etiology and Pathogenesis of Psoriasis
Boehncke, W.-H. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.07.013 · Cited by 197
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
Lebwohl, M. G., Papp, K. A., Marangell, L. B., Koo, J., Blauvelt, A., Gooderham, M., Wu, J. J., Rastogi, S., Harris, S., Pillai, R., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.08.024 · Cited by 179
“Brodalumab, a fully human antieIL-17 receptor A monoclonal antibody, is the first biologic to treat psoriasis that acts directly as an IL-17 receptor antagonist.(15) Brodalumab demonstrated efficacy in 3 large phase 3 psoriasis clinical trials in which Psoriasis Area and Severity Index 100 response rates were signific…”
Self-citationCurrent Concepts of Psoriasis Immunopathogenesis
Vičić, M., Kaštelan, M., Brajac, I., Sotošek, V., & Massari, L. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111574 · Cited by 163
IL-12-and IL-23 in health and disease
Croxford, A. L., Kulig, P., & Becher, B. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.017 · Cited by 160
The problem of choice: current biologic agents and future prospects in RA
Choy, E. H., Kavanaugh, A. F., & Jones, S. A. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.8 · Cited by 141
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
The deubiquitinase A20 mediates feedback inhibition of interleukin-17 receptor signaling
Garg, A. V., Ahmed, M., Vallejo, A. N., Ma, A., & Gaffen, S. L. (2013) · Science Signaling · doi:10.1126/scisignal.2003699 · Cited by 128
Kunzmann, L. K., Schoknecht, T., Poch, T., Henze, L., Stein, S., Kriz, M., Grewe, I., Preti, M., Hartl, J., Pannicke, N., et al. (2020) · Hepatology · doi:10.1002/hep.31140 · Cited by 93
Self-citationAl-Riyami, L., Pineda, M. A., Rzepecka, J., Huggan, J. K., Khalaf, A. I., Suckling, C. J., Scott, F. J., Rodgers, D. T., Harnett, M. M., & Harnett, W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401251p · Cited by 94
Pavelka, K., Chon, Y., Newmark, R., Lin, S.-L., Baumgartner, S., & Erondu, N. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141271 · Cited by 83
Amatya, N., Childs, E. E., Cruz, J. A., Aggor, F. E. Y., Garg, A. V., Berman, A. J., Gudjonsson, J. E., Atasoy, U., & Gaffen, S. L. (2018) · Science Signaling · doi:10.1126/scisignal.aat4617 · Cited by 75
“Blocking IL-17 is remarkably effective in treating psoriasis and is under evaluation for other autoimmune conditions (59, 60).”
Interleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis
Ferreira, M. C., Whibley, N., Mamo, A. J., Siebenlist, U., Chan, Y. R., & Gaffen, S. L. (2014) · Infection and Immunity · doi:10.1128/iai.01389-13 · Cited by 72
The origin and role of innate lymphoid cells in the lung
Lai, D.-M., Shu, Q., & Fan, J. (2016) · Military Medical Research · doi:10.1186/s40779-016-0093-2 · Cited by 45
Two-year US Pharmacovigilance report on Brodalumab
Lebwohl, M., Leonardi, C., Wu, J. J., Armstrong, A., Rawnsley, N., Merchant, M., Alexander, B., & Jacobson, A. (2021) · Dermatology and Therapy · doi:10.1007/s13555-020-00472-x · Cited by 24
Self-citationEffect of steroids and relevant cytokine analysis in acute tubulointerstitial nephritis
Yun, D., Jang, M.-J., An, J. N., Lee, J. P., Kim, D. K., Chin, H. J., Kim, Y. S., Lee, D.-S., & Han, S. S. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1277-2 · Cited by 22
Metadata
- Authors
- Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., & Baumgartner, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-29
- Volume
- 366
- Issue
- 13
- Pages
- 1181-1189
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127834887
- Cited by
- 941
- References
- 28
- FWCI
- 58.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.